Ca 1.3-selective Inhibitors of Voltage-gated L-type Ca Channels: Fact or (still) Fiction?

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2023 Feb 14

PMID 36788128

Authors

Ludovica Filippini

Nadine J Ortner

Teresa Kaserer

Jorg Striessnig

Affiliations

Soon will be listed here.

Abstract

Voltage-gated L-type Ca -channels (LTCCs) are the target of Ca -channel blockers (CCBs), which are in clinical use for the evidence-based treatment of hypertension and angina. Their cardiovascular effects are largely mediated by the Ca 1.2-subtype. However, based on our current understanding of their physiological and pathophysiological roles, Ca 1.3 LTCCs also appear as attractive drug targets for the therapy of various diseases, including treatment-resistant hypertension, spasticity after spinal cord injury and neuroprotection in Parkinson's disease. Since CCBs inhibit both Ca 1.2 and Ca 1.3, Ca 1.3-selective inhibitors would be valuable tools to validate the therapeutic potential of Ca 1.3 channel inhibition in preclinical models. Despite a number of publications reporting the discovery of Ca 1.3-selective blockers, their selectivity remains controversial. We conclude that at present no pharmacological tools exist that are suitable to confirm or refute a role of Ca 1.3 channels in cellular responses. We also suggest essential criteria for a small molecule to be considered Ca 1.3-selective.

Citing Articles

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets.

Lee H, Elkamhawy A, Rakhalskaya P, Lu Q, Nada H, Quan G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770531 PMC: 11677913. DOI: 10.3390/ph17121688.

Altered Protein Kinase A-Dependent Phosphorylation of Cav1.2 in Left Ventricular Myocardium from Haploinsufficient Rat Hearts.

Konigstein D, Fender H, Plackic J, Kisko T, Wohr M, Kockskamper J Int J Mol Sci. 2025; 25(24.

PMID: 39769475 PMC: 11678006. DOI: 10.3390/ijms252413713.

The L-type calcium channel CaV1.3: A potential target for cancer therapy.

Liu X, Shen B, Zhou J, Hao J, Wang J J Cell Mol Med. 2024; 28(19):e70123.

PMID: 39365143 PMC: 11451265. DOI: 10.1111/jcmm.70123.

Novel protocol for multiple-dose oral administration of the L-type Ca channel blocker isradipine in mice: A dose-finding pharmacokinetic study.

Theiner T, Ortner N, Oberacher H, Stojanovic G, Tuluc P, Striessnig J Channels (Austin). 2024; 18(1):2335469.

PMID: 38564754 PMC: 10989688. DOI: 10.1080/19336950.2024.2335469.

Selective blockade of Ca1.2 (α1C) versus Ca1.3 (α1D) L-type calcium channels by the black mamba toxin calciseptine.

Mesirca P, Chemin J, Barrere C, Torre E, Gallot L, Monteil A Nat Commun. 2024; 15(1):54.

PMID: 38167790 PMC: 10762068. DOI: 10.1038/s41467-023-43502-w.

References

Marcantoni M, Fuchs A, Low P, Bartsch D, Kiehn O, Bellardita C . Early delivery and prolonged treatment with nimodipine prevents the development of spasticity after spinal cord injury in mice. Sci Transl Med. 2020; 12(539). DOI: 10.1126/scitranslmed.aay0167. View

. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann Intern Med. 2020; 172(9):591-598. PMC: 7465126. DOI: 10.7326/M19-2534. View

Li Y, Bennett D . Persistent sodium and calcium currents cause plateau potentials in motoneurons of chronic spinal rats. J Neurophysiol. 2003; 90(2):857-69. DOI: 10.1152/jn.00236.2003. View

Ortner N, Bock G, Vandael D, Mauersberger R, Draheim H, Gust R . Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators. Nat Commun. 2014; 5:3897. PMC: 4083433. DOI: 10.1038/ncomms4897. View

Zamponi G, Striessnig J, Koschak A, Dolphin A . The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015; 67(4):821-70. PMC: 4630564. DOI: 10.1124/pr.114.009654. View

Benkert J, Hess S, Roy S, Beccano-Kelly D, Wiederspohn N, Duda J . Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson's disease. Nat Commun. 2019; 10(1):5094. PMC: 6841684. DOI: 10.1038/s41467-019-12834-x. View

Koschak A, Reimer D, Huber I, Grabner M, Glossmann H, Engel J . alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001; 276(25):22100-6. DOI: 10.1074/jbc.M101469200. View

Kang S, Cooper G, Dunne S, Luan C, Surmeier D, Silverman R . Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. J Med Chem. 2013; 56(11):4786-97. PMC: 4595045. DOI: 10.1021/jm4005048. View

Surmeier D, Obeso J, Halliday G . Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017; 18(2):101-113. PMC: 5564322. DOI: 10.1038/nrn.2016.178. View

10.

Degoulet M, Stelly C, Ahn K, Morikawa H . L-type Ca²⁺ channel blockade with antihypertensive medication disrupts VTA synaptic plasticity and drug-associated contextual memory. Mol Psychiatry. 2015; 21(3):394-402. PMC: 4689680. DOI: 10.1038/mp.2015.84. View

11.

Baig S, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G . Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat Neurosci. 2010; 14(1):77-84. DOI: 10.1038/nn.2694. View

12.

Yang T, He M, Zhang H, Barrett P, Hu C . L- and T-type calcium channels control aldosterone production from human adrenals. J Endocrinol. 2019; 244(1):237-247. PMC: 7108971. DOI: 10.1530/JOE-19-0259. View

13.

Huang H, Ng C, Yu D, Zhai J, Lam Y, Soong T . Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent. Nat Commun. 2014; 5:4481. PMC: 4124865. DOI: 10.1038/ncomms5481. View

14.

Lieb A, Scharinger A, Sartori S, Sinnegger-Brauns M, Striessnig J . Structural determinants of CaV1.3 L-type calcium channel gating. Channels (Austin). 2012; 6(3):197-205. PMC: 3431584. DOI: 10.4161/chan.21002. View

15.

Filippini L, Ortner N, Kaserer T, Striessnig J . Ca 1.3-selective inhibitors of voltage-gated L-type Ca channels: Fact or (still) fiction?. Br J Pharmacol. 2023; 180(10):1289-1303. PMC: 10953394. DOI: 10.1111/bph.16060. View

16.

Scholl U, Goh G, Stolting G, de Oliveira R, Choi M, Overton J . Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013; 45(9):1050-4. PMC: 3876926. DOI: 10.1038/ng.2695. View

17.

Billingsley K, Manca M, Gianfrancesco O, Collier D, Sharp H, Bubb V . Regulatory characterisation of the schizophrenia-associated CACNA1C proximal promoter and the potential role for the transcription factor EZH2 in schizophrenia aetiology. Schizophr Res. 2018; 199:168-175. PMC: 6179964. DOI: 10.1016/j.schres.2018.02.036. View

18.

Tenti G, Parada E, Leon R, Egea J, Martinez-Revelles S, Briones A . New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury. J Med Chem. 2014; 57(10):4313-23. DOI: 10.1021/jm500263v. View

19.

Surmeier D, Halliday G, Simuni T . Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Exp Neurol. 2017; 298(Pt B):202-209. PMC: 6037988. DOI: 10.1016/j.expneurol.2017.08.001. View

20.

Guzman J, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker P . Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010; 468(7324):696-700. PMC: 4465557. DOI: 10.1038/nature09536. View